BioPharma Credit PLC Transaction in Own Shares (0657A)
18 January 2024 - 5:15AM
UK Regulatory
TIDMBPCR
RNS Number : 0657A
BioPharma Credit PLC
17 January 2024
BioPharma Credit plc
(the "Company")
TRANSACTION IN OWN SHARES
BioPharma Credit PLC (the "Company") announces that today it has
purchased the following number of its ordinary shares of US$0.01
each on the London Stock Exchange through J.P. Morgan Securities
plc into treasury.
Ordinary Shares: BPCR LN
Date of purchase: 17 January 2024
Number of ordinary shares purchased: 474,383
Lowest price per share: $0.9380
Highest price per share: $0.9400
Trading venue: London Stock Exchange
Ordinary Shares: BPCR LN
Date of purchase: 17 January 2024
Number of ordinary shares purchased: 500,000
Lowest price per share: $0.9400
Highest price per share: $0.9400
Trading venue: JPSI
Aggregate volume per date per trading venue: 974,383
Weighted average price per day per trading venue: $0.9400
Following the above transaction, the Company holds 85,207,288 of
its ordinary shares in treasury and has 1,288,724,779 ordinary
shares in issue (excluding treasury shares). Therefore, the total
number of voting rights in the Company is 1,288,724,779. This
figure may be used by shareholders as the denominator for the
calculations by which they will determine if they are required to
notify their interest in, or a change to their interest in, the
Company under the FCA's Disclosure Guidance and Transparency
Rules.
Enquiries:
BioPharma Credit plc
via Link Company Matters Limited
Company Secretary
+44 (0) 333 300 1950
Buchanan
David Rydell / Mark Court / Jamie Hooper / Henry Wilson
+44 (0)20 7466 5000
biopharmacredit@buchanan.uk.com
Notes to Editors:
BioPharma Credit PLC is London's only specialist debt investor
to the life sciences industry and joined the LSE in March 2017.
BioPharma Credit PLC seeks to provide long-term shareholder
returns, principally in the form of sustainable income
distributions from exposure to the life sciences industry.
BioPharma Credit PLC seeks to achieve this objective primarily
through investments in debt assets secured by royalties or other
cash flows derived from the sales of approved life sciences
products.
LEI: 213800AV55PYXAS7SY24
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
POSDDLFFZFLZBBV
(END) Dow Jones Newswires
January 17, 2024 13:15 ET (18:15 GMT)
Biopharma Credit (LSE:BPCP)
Historical Stock Chart
From Nov 2024 to Dec 2024
Biopharma Credit (LSE:BPCP)
Historical Stock Chart
From Dec 2023 to Dec 2024